Here’s Why Merck & Co., Inc. (NYSE:MRK) Shares Are Going Crazy Today
MRK Stock Is Soaring…
Mega-cap stocks are not known for making big moves. But on Tuesday, January 16, shares of Merck & Co., Inc. (NYSE:MRK) surged more than eight percent within about one hour after the market opened. That’s quite a surge for a well-established pharmaceutical company commanding more than $170.0 billion in market cap.
The big question, of course, is: why did Merck shares jump by so much? So let’s take a look.
On Tuesday morning, Merck announced positive results from its Phase 3 KEYNOTE-189 Trial. The results suggest that the company’s “Keytruda” drug, along with two chemotherapy medicines, met the dual primary endpoints of overall survival (OS) and progression-free survival for the first-line treatment of lung cancer patients. In other words, the trial showed that this combination helped lung cancer patients live longer and prevented the disease from advancing. (Source: “Merck’s KEYTRUDA(R) (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment in Combination with Pemetrexed and Platinum Chemotherapy for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (KEYNOTE-189),” Merck & Co., Inc., January 16, 2018.)
“KEYNOTE-189 showed significant improvement in overall survival and progression-free survival for patients receiving KEYTRUDA in the first-line setting in combination with traditional chemotherapy, compared with those receiving chemotherapy alone,” said Dr. Roger M. Perlmutter, president of Merck Research Laboratories. “We are deeply grateful to the KEYNOTE-189 patients and investigators for their important contributions to this landmark study, and we look forward to presenting the data in the near future,” he added. (Source: Ibid.)
This is a big deal for the American pharmaceutical company. Previously, Merck has said that the results from this trial wouldn’t be unveiled until 2019, so Tuesday’s announcement came as a nice surprise. Moreover, these results reinforced Merck’s position as the leader in the race to develop drugs used in first-line treatment for lung cancer. So unsurprisingly, the company’s rivals in this race saw their share prices drop following the news.
Bristol-Myers Squibb Co (NYSE:BMY) stock was down five percent, Roche Hldings AG (OTCMKETS:RHHBY) fell 3.6%, while AstraZeneca plc (NYSE:AZN) slipped 1.4%.
Dear Reader: There is no magic formula to getting rich. Success in investment vehicles with the best prospects for price appreciation can only be achieved through proper and rigorous research and analysis. We are 100% independent in that we are not affiliated with any bank or brokerage house. Information contained herein, while believed to be correct, is not guaranteed as accurate. Warning: Investing often involves high risks and you can lose a lot of money. Please do not invest with money you cannot afford to lose. The opinions in this content are just that, opinions of the authors. We are a publishing company and the opinions, comments, stories, reports, advertisements and articles we publish are for informational and educational purposes only; nothing herein should be considered personalized investment advice. Before you make any investment, check with your investment professional (advisor). We urge our readers to review the financial statements and prospectus of any company they are interested in. We are not responsible for any damages or losses arising from the use of any information herein. Past performance is not a guarantee of future results. All registered trademarks are the property of their respective owners
Sign up to receive our FREE Income Investors newsletter along with our special offers and get our FREE report:
5 Dividend Stocks to Own Forever
This is an entirely free service. No credit card required. You can opt-out at anytime.
We hate spam as much as you do.